Search all articles within the Clem Jones Centre for Neurobiology and Stem Cell Research topic
A world-first trial to help improve the lives of Australians living with a debilitating spinal cord injury is a step closer with a $6.8 million Medical Research Future Fund grant.
A state-of-the-art livecyte microscope at the Griffith Institute for Drug Discovery is leading the Spinal Injury Project team toward human clinical trials.
A pilot smell clinic has commenced at Griffith’s Gold Coast campus in a bid to gather more data on how microorganisms within the nose can contribute to Alzheimer’s disease.
Calls for more study to be conducted into how microorganisms contribute to the onset and progression of Alzheimer’s disease.
Griffith University’s world-first study into cell transplantation to repair injuries to the nervous system has received a major boost thanks to a $5.4 million funding extension from the MAIC.
Griffith University is paying tribute to one of its finest in Professor Emeritus Alan Mackay-Sim AM known to many as...
Queensland will become a global mRNA vaccine hub with global healthcare company Sanofi partnering with Griffith University and other leading research institutions to establish a world-first research centre in south east Queensland.
Griffith University is seeking five people living with spinal cord injury to be part of stage two of an innovative trial which will test intensive rehabilitation for those living with chronic spinal cord paralysis.
Griffith University researchers have demonstrated that a bacteria can travel through the olfactory nerve in the nose and into the brain in mice, where it creates markers that are a tell-tale sign of Alzheimer’s disease.
A bacterium commonly present in the nose can sneak into the brain and may increase the risk of Alzheimer’s disease.
